Accordingly, PARP-1 is an attractive anticancer target, and poly(ADP-ribose) polymerase (PARP) inhibitors have been identified as chemo- and radiation-sensitizing agents in an array of cancers (2–5), including our report on the sensitization of head and neck cancer to radiotherapy following PARP inhibition (6). Here, PARP1 is linked to head and neck cancer.